The AltaValve system for transcatheter mitral valve replacement: A narrative review of early safety and efficacy data

Mitral regurgitation (MR) is a prevalent and progressive condition associated with poor outcomes in high-risk patients who are often ineligible for surgery or transcatheter repair. The AltaValve system (4C Medical Technologies, Maple Grove, MN), a novel transcatheter mitral valve replacement (TMVR) device, employs a unique supra-annular, atrial-only fixation mechanism designed to minimize left ventricular outflow tract (LVOT) obstruction and paravalvular leak. This narrative review summarizes current clinical evidence on AltaValve, including case reports, single-center, and multicenter experiences, as well as findings from the recent AltaValve Early Feasibility Study. Across diverse patient populations, such as those with functional, primary, and atrial MR, the device has demonstrated high technical success, favorable safety, and significant reduction in MR severity. Transseptal delivery has emerged as a less invasive and safer approach compared to transapical access, further expanding the device's applicability. Short-term follow-up reveals consistent improvement in hemodynamics, functional capacity, and quality of life measures, with low procedural complication rates. No cases of valve embolization, significant thrombosis, or structural degeneration have been reported yet. While early outcomes are promising, the data are limited to small, non-randomized cohorts, and long-term durability remains to be established. The AltaValve system represents a significant step forward in TMVR, particularly for patients with anatomically complex or inoperable MR. Ongoing pivotal trials will be essential to confirm its role within the transcatheter valve therapy landscape.